Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FOSTAMATIN · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Period 1 | EXPERIMENTAL | - |
| Period 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| FOSTAMATIN | DRUG | Oral tablets - single dose |
| Verapamil | DRUG | Oral tablets - administered 3 times daily over 4 days |
Inclusion Criteria: * Weight of at least 50 kg (110 lbs) and body mass index (BMI) between 18 and 35 kg/m2, inclusive. * Females must be of non-childbearing potential Exclusion Criteria: * History of clinically significant disease or disorder or presence of GI, hepatic or renal disease * Any clin...
FOSTAMATIN is a small molecule being studied for its potential in drug-drug interactions. It was evaluated in a Phase 1 clinical trial involving healthy volunteers to assess how it interacts when taken together with verapamil. The study focused on healthy volunteers rather than patients with a specific disease.
FOSTAMATIN is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting clinical research on this small molecule, with the drug currently in Phase 1 development.
FOSTAMATIN is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical research.
FOSTAMATIN has been studied in one clinical trial with the identifier NCT01197781. This Phase 1 study, titled "Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers," was completed in the United States and enrolled 15 participants.
Yes, FOSTAMATIN is also known as FosD. In the clinical trial NCT01197781, the drug is referred to as FosD, and the study evaluates the drug-drug interaction between FosD and verapamil when taken together in healthy volunteers.